Noguchi M, Koga N, Moriya F, et al. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers. Cancer Sci. 2018;109:2660--2669. 10.1111/cas.13709 29938870

**Clinical Trials Registry:** UMIN000001850, UMIN000005329, UMIN000010290, UMIN000001854 and UMIN000003157.

CI

:   confidence interval

CP

:   correlated peptide

CRPC

:   castration‐resistant prostate cancer

HLA

:   human leukocyte antigen

HR

:   hazard ratio

IFN‐γ

:   interferon‐γ

IHC

:   immunohistochemical staining

OS

:   overall survival

PAP

:   prostatic acid phosphatase

PPV

:   personalized peptide vaccine

PS

:   performance status

PSA

:   prostate‐specific antigen

PSMA

:   prostate‐specific membrane antigen

TAA

:   tumor‐associated antigen

TIL

:   tumor‐infiltrating lymphocyte

UC

:   urothelial cancer

1. INTRODUCTION {#cas13709-sec-0001}
===============

Peptide‐based cancer vaccines are considered a promising therapeutic strategy; however, their clinical results have been unsatisfactory for the past 2 decades.[1](#cas13709-bib-0001){ref-type="ref"}, [2](#cas13709-bib-0002){ref-type="ref"}, [3](#cas13709-bib-0003){ref-type="ref"} One reason for this is the difficulty in selecting efficient TAA because of the heterogeneity of tumor cells and the diversity of immune responses. After much consideration, PPV was developed in which individual patients are vaccinated with multiple peptides based on HLA type and pre‐existing immunity by measuring peptide‐specific IgG levels. The clinical benefits of PPV for several advanced urological cancers, including CRPC and advanced UC, have been reported in clinical trials.[4](#cas13709-bib-0004){ref-type="ref"}, [5](#cas13709-bib-0005){ref-type="ref"}, [6](#cas13709-bib-0006){ref-type="ref"} However, there are several concerns to be addressed to develop more efficacious PPV treatment for precision immunotherapy. One is how to determine more clinically effective peptides from IgG‐positive peptide candidates prior to PPV treatment. Although all candidate peptides provided for PPV treatment had equal capability to induce CTL activity in vitro in PBMC, and pre‐existing IgG responses to these peptides were equally detectable in cancer patients,[3](#cas13709-bib-0003){ref-type="ref"}, [7](#cas13709-bib-0007){ref-type="ref"}, [8](#cas13709-bib-0008){ref-type="ref"} equal capability of each peptide at the clinical level is not guaranteed, and there are no methods available to discriminate clinically efficacious peptides among the candidates prior to PPV treatment.

We aimed to evaluate the selection of clinically correlated peptides based on OS according to HLA types in 154 patients with CRPC and in 111 patients with advanced UC treated by PPV.

2. PATIENTS AND METHODS {#cas13709-sec-0002}
=======================

2.1. Candidate peptides {#cas13709-sec-0003}
-----------------------

In PPV treatment, 31 candidate peptides from 15 TAA were prepared under the conditions of Good Manufacturing Practice using a Multiple Peptide System (San Diego, CA, USA). All 31 candidate peptides were CTL epitopes restricted to the HLA‐A2, ‐A24 or ‐A3 families (HLA‐A3, ‐A11, ‐A31 or ‐A33) of MHC class I molecules, which covered the majority of the general population. Names of peptides, coding TAA, amino acid sequences, and HLA types are given in Table [1](#cas13709-tbl-0001){ref-type="table"}. Expression levels of the 15 TAA that code the peptides used for PPV treatment were examined by IHC of primary prostate cancer tissues (n = 10), metastatic lymph nodes from prostate cancer (n = 4), and primary UC tissues (n = 10) obtained from nonvaccinated patients. Detailed methods, including antibodies used for staining, were previously described.[7](#cas13709-bib-0007){ref-type="ref"}, [9](#cas13709-bib-0009){ref-type="ref"}, [10](#cas13709-bib-0010){ref-type="ref"}, [11](#cas13709-bib-0011){ref-type="ref"}, [12](#cas13709-bib-0012){ref-type="ref"}, [13](#cas13709-bib-0013){ref-type="ref"}, [14](#cas13709-bib-0014){ref-type="ref"}, [15](#cas13709-bib-0015){ref-type="ref"}, [16](#cas13709-bib-0016){ref-type="ref"}, [17](#cas13709-bib-0017){ref-type="ref"}

###### 

Candidate peptides used in the present study

  Peptide name   Source TAA      Position of peptide   Amino acid sequence   HLA type
  -------------- --------------- --------------------- --------------------- ------------------------------------------------------
  SART2‐93       SART2           93‐101                DYSARWNEI             A24
  SART3‐109      SART3           109‐118               VYDYNCHVDL            A24,A3 family[a](#cas13709-note-0002){ref-type="fn"}
  Lck‐208        p56 lck         208‐216               HYTNASDGL             A24
  PAP‐213        PAP             213‐221               LYCESVHNF             A24
  PSA‐248        PSA             248‐257               HYRKWIKDTI            A24
  EGFR‐800       EGF‐R           800‐809               DYVREHKDNI            A24
  MRP3‐503       MRP3            503‐511               LYAWEPSFL             A24
  MRP3‐1293      MRP3            1293‐1302             NYSVRYRPGL            A24
  SART2‐161      SART2           161‐169               AYDFLYNYL             A24
  Lck‐486        p56 lck         486‐494               TFDYLRSVL             A24
  Lck‐488        p56 lck         488‐497               DYLRSVLEDF            A24
  PSMA‐624       PSMA            624‐632               TYSVSFDSL             A24
  EZH2‐735       EZH2            735‐743               KYVGIEREM             A24
  PTHrP‐102      PTHrP           102‐111               RYLTQETNKV            A24
  CypB‐129       Cyclophilin B   129‐138               KLKHYGPGWV            A2,A3 family[a](#cas13709-note-0002){ref-type="fn"}
  Lck‐246        p56 lck         246‐254               KLVERLGAA             A2
  Lck‐422        p56 lck         422‐430               DVWSFGILL             A2,A3 family[a](#cas13709-note-0002){ref-type="fn"}
  MAP‐432        ppMAPkkk        432‐440               DLLSHAFFA             A2
  WHSC2‐103      WHSC2           103‐111               ASLDSDPWV             A2,A3 family[a](#cas13709-note-0002){ref-type="fn"}
  HNRPL‐501      HNRPL           501‐510               NVLHFFNAPL            A2
  UBE‐43         UBE2V           43‐51                 RLQEWCSVI             A2
  UBE‐85         UBE2V           85‐93                 LIADFLSGL             A2
  WHSC2‐141      WHSC2           141‐149               ILGELREKV             A2
  HNRPL‐140      HNRPL           140‐148               ALVEFEDVL             A2
  SART3‐302      SART3           302‐310               LLQAEAPRL             A2
  SART3‐309      SART3           309‐317               RLAEYQAYI             A2
  SART3‐511      SART3           511‐519               WLEYYNLER             A3 family[a](#cas13709-note-0002){ref-type="fn"}
  SART3‐734      SART3           734‐742               QIRPIFSNR             A3 family[a](#cas13709-note-0002){ref-type="fn"}
  Lck‐90         p56 lck         90‐99                 ILEQSGEWWK            A3 family[a](#cas13709-note-0002){ref-type="fn"}
  Lck‐449        p56 lck         449‐458               VIQNLERGYR            A3 family[a](#cas13709-note-0002){ref-type="fn"}
  PAP‐248        PAP             248‐257               GIHKQKEKSR            A3 family[a](#cas13709-note-0002){ref-type="fn"}

A3 family, HLA‐A3, A11, A31 and A33.

HLA, human leukocyte antigen; TAA, tumor‐associated antigen.
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2.2. Patient selection {#cas13709-sec-0004}
----------------------

From April 2009 to April 2013, the Cancer Vaccine Center of Kurume University in Japan conducted 5 prospective phase II clinical trials of PPV treatment for advanced urological cancers involving 154 patients with CRPC (UMIN Clinical Trials Registry: UMIN000001850, UMIN000005329 and UMIN000010290) and 111 patients with advanced UC progressing after platinum‐containing chemotherapy (UMIN Clinical Trials Registry: UMIN000001854 and UMIN000003157). Characteristics of the CRPC patients from 3 trials and UC patients from 2 trials were similar. All patients provided written informed consent for study participation and data collection. The results of all 5 clinical trials were reported previously.[6](#cas13709-bib-0006){ref-type="ref"}, [18](#cas13709-bib-0018){ref-type="ref"}, [19](#cas13709-bib-0019){ref-type="ref"}, [20](#cas13709-bib-0020){ref-type="ref"}, [21](#cas13709-bib-0021){ref-type="ref"} In the present study, the data of these trials were used to analyze the peptides that correlated with clinical benefits. Common inclusion or exclusion criteria for the 5 clinical trials of PPV treatment were as follows: eligible patients were aged ≥18 years and had ECOG PS of 0 or 1, life expectancy of at least 12 weeks, positive HLA‐A2, ‐A24 or ‐A3 family (‐A3, ‐A11, ‐A31 and ‐A33) status, positive IgG responses to at least 2 of the 31 different candidate peptides, and adequate bone marrow function, hepatic function and renal function. Exclusion criteria included acute infection, history of severe allergic reactions, pulmonary, cardiac or other systemic diseases, or other inappropriate conditions for enrollment as judged by clinicians. The procedure for PPV treatment was as follows. Each of the selected peptides based on HLA type and level of IgG titer was mixed with incomplete Freund\'s adjuvant (Montanide ISA‐51VG; Seppic, Paris, France), and a 1.5‐mL emulsion (3 mg/peptide) of a maximum of 4 peptides was injected s.c. into the lateral thigh area once a week for 6 or 8 weeks as the first cycle of PPV treatment. After the first cycle, PPV dosage was carried out in 2‐, 3‐ or 4‐week intervals until withdrawal of consent or unacceptable toxicity.

2.3. Estimation of clinical efficacy of individual peptides {#cas13709-sec-0005}
-----------------------------------------------------------

According to HLA type, survival data for each patient were divided into 2 groups, with or without individual peptides, using individual peptides at the first cycle. Cox proportional hazards regression analyses were then carried out to calculate HR, 95% CI, and *P*‐values for the treatment effects of individual peptides in relation to OS, and to select peptides that correlated with OS. Peptides used for only a few patients (\<10%) were excluded from the Cox proportional hazards regression analyses to avoid bias.

2.4. Immune responses to individual peptides {#cas13709-sec-0006}
--------------------------------------------

Individual peptide‐specific IgG and CTL responses were analyzed in blood samples before and after the first cycle of PPV treatment. IgG responses were measured by the Luminex system (Luminex, Austin, TX, USA) using plasma, and the CTL responses were evaluated by IFN‐γ ELISPOT assay (MBL, Nagoya, Japan) using PBMC as previously described.[22](#cas13709-bib-0022){ref-type="ref"}, [23](#cas13709-bib-0023){ref-type="ref"} Higher IgG titers to vaccinated peptides at the end of the first cycle than those in prevaccination plasma and more than 30 spots for the corresponding peptide in PBMC as observed by IFN‐γ ELISPOT assay were considered to be positive immune responses.

2.5. Statistics {#cas13709-sec-0007}
---------------

Baseline characteristics, vaccinated peptides, immunological responses to vaccinated peptides, OS during PPV treatment, and follow up were extracted from the database of the 5 clinical PPV trials. Student\'s *t* test and the chi‐squared test were used to compare quantitative and categorical variables, respectively. OS was calculated as the time in months from the date of study enrollment to death or to the date of last contact. Time‐to‐event endpoints were analyzed using the Kaplan‐Meier method, and between‐group comparisons for OS were conducted using the log‐rank test. Clinical efficacy of individual peptides for OS was evaluated by univariate and multivariate analyses with the Cox proportional hazards regression model, and HR and 95% CI were calculated. Favorable peptides for clinical efficacy (HR \<1.0) in the univariate analysis were included in the multivariate analysis. All reported *P*‐values were 2‐sided, and *P*‐values \<.05 were considered significant. JMP version 12 or SAS version 9.4 software (SAS Institute Inc., Cary, NC, USA) was used to carry out all analyses.

3. RESULTS {#cas13709-sec-0008}
==========

3.1. Expression of tumor antigens {#cas13709-sec-0009}
---------------------------------

In the 10 primary prostate cancer tissues tested, 4 TAA (PSA, PSMA, PTHrP, and CypB) were highly expressed in the majority (\>80%) of tumor cells and nonmalignant cells, whereas 6 TAA (PAP, UBE2V, HNRPL, SART2, SART3, and ppMAPkkk) were modestly expressed in the majority (\>80%) of tumor cells and nonmalignant cells. WHSC2 and epidermal growth factor receptor (EGFR) were expressed in half of the tumor cells and nonmalignant cells from 5 samples. There were no TAA expressed only in nonmalignant cells. Although p56Lck was not expressed in any tumor cells tested, it was expressed in TIL from all samples. EZH2 and MRP3 were not expressed in any tumor cells or nonmalignant cells from the 10 samples tested. Four metastatic lymph nodes from advanced prostate cancer patients were also provided for the study and showed similar results as above with the exception of EZH2 and MRP3, which became detectable in 3 and 1 of the 4 samples tested, respectively. Representative results of IHC in prostate cancer tissues are shown in Figure [1](#cas13709-fig-0001){ref-type="fig"}A.

![Representative results of expression of 15 tumor‐associated antigens (TAA) evaluated by immunohistochemical staining in prostate cancer (A) and urothelial cancer tissues (B)](CAS-109-2660-g001){#cas13709-fig-0001}

In the 10 primary UC tissues tested, 5 TAA (SART2, SART3, EZH2, ppMAPkkk, and WHSC2) were highly expressed in the majority of both tumor cells and nonmalignant cells, whereas 4 TAA (UBE2V, HNRPL, PTHrP, and EGFR) were modestly expressed in the majority of both tumor cells and normal cells. CypB and MRP3 were expressed in both tumor cells and nonmalignant cells from 6 and 3 of 10 samples tested, respectively. Similar to the results of IHC for prostate cancer tissues, p56Lck was not expressed in any of the tumor cells tested but was expressed in TIL from all samples. PSA, PAP, and PSMA were not expressed in any urothelial cancer cells or normal cells from the 10 samples tested. Representative results of IHC in urothelial cancer tissues are shown in Figure [1](#cas13709-fig-0001){ref-type="fig"}B.

3.2. Baseline characteristics {#cas13709-sec-0010}
-----------------------------

Table [2](#cas13709-tbl-0002){ref-type="table"} shows the baseline characteristics of the advanced urological cancer patients analyzed in this study classified by HLA type. There was no significant difference in age, PS, PSA levels, Gleason score, metastatic site or prior chemotherapy in CRPC patients among HLA types, or in age, PS, primary tumor site, metastatic site or prior chemotherapy in advanced UC patients among HLA types. All patients were refractory to the first‐line treatment or chemotherapy.

###### 

Baseline characteristics of advanced urological cancer patients

  Factor                  CRPC (n = 154)   Advanced UC (n = 111)                                                             
  ----------------------- ---------------- ----------------------- ---------- ---------- ----------- ----------- ----------- -----
  Age, y                                                                                                                     
  Median                  68               70                      70         .57        65          66.5        63.5        .81
  Range                   43‐85            59‐84                   60‐82      42‐83      40‐80       45‐78                   
  Gender                                                                                                                     
  Male                    102              35                      17         ---        53 (73%)    17 (77%)    13 (81%)    .79
  Female                  ---              ---                     ---        19 (26%)   5 (23%)     3 (19%)                 
  ECOG PS                                                                                                                    
  0                       83 (81%)         26 (74%)                15 (88%)   .46        59 (81%)    15 (68%)    13 (81%)    .43
  1                       19 (19%)         9 (26%)                 2 (12%)    14 (19%)   7 (32%)     3 (19%)                 
  PSA, ng/mL                                                                                                                 
  Median                  38.5             17.9                    20.2       .31        ---         ---         ---         ---
  Range                   0‐10 895         0.02‐741                1.4‐278    ---        ---         ---                     
  Gleason score                                                                                                              
  \<8                     22 (22%)         11 (31%)                3 (18%)    .41        ---         ---         ---         ---
  \>8                     80 (78%)         24 (69%)                14 (82%)   ---        ---         ---                     
  Primary tumor sites                                                                                                        
  Prostate                102              35                      17         ---        ---         ---         ---         .07
  Bladder                 ---              ---                     ---        40 (55%)   8 (36%)     6 (38%)                 
  Ureter or pelvis        ---              ---                     ---        33 (45%)   14 (64%)    10 (62%)                
  Metastatic sites                                                                                                           
  None                    7 (7%)           2 (6%)                  1 (6%)     .08        6 (8%)      1 (5%)      1 (5.5%)    .18
  Lymph node only         12 (12%)         2 (6%)                  2 (12%)    22 (30%)   7 (32%)     2 (13%)                 
  Bone only               41 (40%)         11 (31%)                7 (41%)    1 (1%)     1 (5%)      1 (5.5%)                
  Lymph node with bone    32 (31%)         16 (46%)                2 (12%)    1 (1%)     0           2 (13%)                 
  Lung only               0                1 (3%)                  1 (6%)     15 (21%)   3 (13%)     4 (25%)                 
  Lymph node with lung                                                        11 (15%)   5 (23%)     0                       
  Others with liver       4 (4%)           0                       1 (6%)     4 (5%)     3 (13%)     4 (25%)                 
  Others without liver    6 (6%)           3 (8%)                  3 (17%)    14 (19%)   2 (9%)      2 (13%)                 
  Prior radical surgery   17 (17%)         1 (3%)                  1 (6%)     .07        43 (59%)    10 (46%)    11 (58%)    .33
  Prior irradiation       40 (39%)         6 (17%)                 6 (35%)    .06        1 (1%)      0           0           .77
  Prior docetaxel         57 (56%)         18 (51%)                6 (35%)    .29        ---         ---         ---         
  Prior GC or MVAC        ---              ---                     ---                   73 (100%)   22 (100%)   16 (100%)   ---
  Vaccination, times                                                                                                         
  Median                  18               17                      15                    10          8           11.5        
  Range                   2‐68             6‐46                    1‐48                  1‐44        1‐29        2‐38        
  Follow up, months                                                                                                          
  Median                  20.5             16.2                    17.5                  5.5         6.3         10.5        
  Range                   0.6‐87.4         2.5‐40.4                0.6‐40.7              0.4‐54      1‐72.6      0.9‐49      

CRPC, castration‐resistant prostate cancer; GC, gemcitabine and cisplatin; HLA, human leukocyte antigen; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; PS, performance status; PSA, prostate‐specific antigen; UC, urothelial cancer; ---, not applicable.

John Wiley & Sons, Ltd

3.3. Estimation of correlated peptides {#cas13709-sec-0011}
--------------------------------------

Peptides used in \<10% of all patients were excluded from the univariate Cox regression analysis to avoid bias as follows: Lck208, MRP3‐503, and EZH2‐735 for HLA‐A24, Lck‐422, and UBE2V‐85 for HLA‐A2, and Lck‐422 for the HLA‐A3 family in CRPC patients (Table [3](#cas13709-tbl-0003){ref-type="table"}); MRP3‐503, SART2‐161, and EZH2‐735 for HLA‐A24, Lck‐422, and UBE2V‐85 for HLA‐A2, and Lck‐422 for the HLA‐A3 family in advanced UC patients (Table [4](#cas13709-tbl-0004){ref-type="table"}). The remaining peptides with HR \<1.0 were then used for multivariate Cox regression analysis to calculate the HR, 95% CI and *P*‐values. In CRPC patients, SART3‐109 (HR 0.55, 95% CI 0.31‐0.94; *P *=* *.03) and PTHrP‐102 (HR 0.45, 95% CI 0.18‐0.96; *P *=* *.04) for HLA‐A24, HNPRL‐140 (HR 0.14, 95% CI 0.01‐0.78; *P *=0.02), and SART3‐302 (HR 0.39, 95% CI 0.15‐0.97; *P *=0.04) for HLA‐A2, and Lck‐90 (HR 0.21, 95% CI 0.03‐0.94; *P *=* *.04) for the HLA‐A3 family were considered to be correlated peptides based on significant differences with unused peptides (Table [3](#cas13709-tbl-0003){ref-type="table"}). In advanced UC patients, EGF‐R‐800 (HR 0.35, 95% CI 0.15‐0.73; *P *=* *.005), Lck‐486 (HR 0.54, 95% CI 0.3‐0.97; *P *=* *.04) and PSMA‐624 (HR 0.32, 95% CI 0.1‐0.95; *P *=* *.04) for HLA‐A24, CypB‐129 (HR 0.17, 95% CI 0.03‐0.67; *P *=* *.01) for HLA‐A2, and SART3‐734 for the HLA‐A3 family were also considered to be correlated peptides (Table [4](#cas13709-tbl-0004){ref-type="table"}). All correlated peptides showed peptide‐specific IgG and CTL responses at the end of the first cycle of PPV treatment (Table [5](#cas13709-tbl-0005){ref-type="table"}).

###### 

Univariate and multivariate analyses for contributing peptides in CRPC patients

  HLA                  Peptides    No. of pts with/without   Univariate   Multivariate                                      
  -------------------- ----------- ------------------------- ------------ -------------- ------- ------------- ------------ -----
  A24 (n = 102)        SART2‐93    74/28                     1.14         0.71‐1.9       .60     ---           ---          ---
  *SART3‐109*          21/81       0.58                      0.32‐0.98    .04            0.55    0.31‐0.94     **.03**      
  Lck‐208              8/94        ---                       ---          ---            ---     ---           ---          
  PAP‐213              30/72       1.12                      0.68‐1.79    .64            ---     ---           ---          
  PSA‐248              51/51       1.20                      0.77‐1.87    .41            ---     ---           ---          
  EGF‐R‐800            24/78       1.22                      0.72‐1.96    .45            ---     ---           ---          
  MRP3‐503             7/95        ---                       ---          ---            ---     ---           ---          
  MRP3‐1293            15/87       1.05                      0.53‐1.91    .87            ---     ---           ---          
  SART2‐161            12/90       0.94                      0.45‐1.76    .85            0.9     0.43‐1.7      .77          
  Lck‐486              56/46       1.47                      0.94‐2.32    .09            ---     ---           ---          
  Lck‐488              64/38       1.09                      0.7‐1.73     .70            ---     ---           ---          
  PSMA‐624             10/92       1.23                      0.55‐2.41    .59            ---     ---           ---          
  EZH2‐735             4/98        ---                       ---          ---            ---     ---           ---          
  *PTHrP‐102*          11/91       0.48                      0.19‐1.01    .05            0.454   0.176‐0.962   **.04**      
  A2 (n = 35)          CypB‐129    15/20                     1.07         0.47‐2.41      .87     ---           ---          ---
  Lck‐246              20/15       0.76                      0.34‐1.7     .50            0.59    0.22‐1.59     .29          
  Lck‐422              0/35        ---                       ---          ---            ---     ---           ---          
  ppMAPkkk‐432         11/24       1.59                      0.64‐3.64    .30            ---     ---           ---          
  WHSC2‐103            15/20       1.17                      0.5‐2.64     .70            ---     ---           ---          
  HNRPL‐501            9/26        1.42                      0.55‐3.3     .45            ---     ---           ---          
  UBE2V‐43             15/20       0.86                      0.37‐1.92    .71            1.28    0.476‐3.32    .62          
  UBE2V‐85             3/32        ---                       ---          ---            ---     ---           ---          
  WHSC2‐141            10/25       1.11                      0.43‐2.58    .82            ---     ---           ---          
  *HNRPL‐140*          4/31        0.16                      0.009‐0.79   .02            0.07    0.003‐0.45    **.003**     
  *SART3‐302*          14/21       0.73                      0.31‐1.65    .45            0.39    0.148‐0.968   **.04**      
  SART3‐309            12/23       0.98                      0.4‐2.23     .96            0.64    0.23‐1.64     .36          
  A3 family (n = 17)   SART3‐109   3/14                      0.67         0.1‐2.66       .60     1.19          0.09‐13.69   .88
  SART3‐511            8/9         0.36                      0.08‐1.25    .11            0.60    0.07‐3.85     .6           
  SART3‐734            12/5        0.99                      0.31‐3.75    .98            1.03    0.21‐6.02     .97          
  *Lck‐90*             8/9         0.18                      0.03‐0.72    .01            0.21    0.028‐0.944   **.04**      
  Lck‐449              7/10        2.22                      0.66‐8.57    .20            ---     ---           ---          
  PAP‐248              3/14        0.26                      0.01‐1.39    .13            0.31    0.01‐2.12     .26          
  Lck‐422              1/16        ---                       ---          ---            ---     ---           ---          
  CypB‐129             9/8         4.81                      1.12‐33.13   .03            ---     ---           ---          
  WHSC2‐103            6/11        1.04                      0.27‐3.51    .95            ---     ---           ---          

Peptides used for \<10% of patients were excluded from the univariate analysis.

Correlated peptides are shown in italics and significant *P‐*values are in shown in bold text. CI, confidence interval; CRPC, castration‐resistant prostate cancer; HR, hazard ratio; ---, not applicable.
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###### 

Univariate and multivariate analyses for contributing peptides in advanced UC patients

  HLA                  Peptides     No. of pts with/without   Univariate   Multivariate                                   
  -------------------- ------------ ------------------------- ------------ -------------- ------ ------------ ----------- ---------
  A24 (n = 73)         SART2‐93     51/22                     0.86         0.5‐1.52       .59    0.61         0.32‐1.23   .16
  SART3‐109            10/63        1.31                      0.63‐2.49    .45            ---    ---          ---         
  Lck‐208              14/59        0.83                      0.39‐1.57    .57            0.71   0.3‐1.57     .41         
  PAP‐213              15/58        0.64                      0.32‐1.18    .16            0.52   0.25‐1.02    .06         
  PSA‐248              23/50        0.97                      0.55‐1.63    .90            1.05   0.59‐1.83    .87         
  *EGF‐R‐800*          12/61        0.55                      0.26‐1.04    .07            0.35   0.15‐0.73    **.005**    
  MRP3‐503             3/70         ---                       ---          ---            ---    ---          ---         
  MRP3‐1293            11/62        0.75                      0.35‐1.46    .42            ---    ---          ---         
  SART2‐161            6/67         ---                       ---          ---            ---    ---          ---         
  *Lck‐486*            32/41        0.85                      0.5‐1.41     .53            0.54   0.3 ‐0.97    **.04**     
  Lck‐488              52/21        1.16                      0.67‐2.08    .61            ---    ---          ---         
  *PSMA‐624*           8/65         0.69                      0.24‐1.57    .40            0.32   0.1‐0.95     **.04**     
  EZH2‐735             2/71         ---                       ---          ---            ---    ---          ---         
  PTHrP‐102            11/62        1.33                      0.61‐2.57    .45            ---    ---          ---         
  A2 (n = 22)          *CypB‐129*   9/13                      0.27         0.08‐0.81      .02    0.17         0.03‐0.67   **.01**
  Lck‐246              7/15         0.58                      0.19‐1.61    .30            0.33   0.07‐1.24    .1          
  Lck‐422              1/21         ---                       ---          ---            ---    ---          ---         
  ppMAPkkk‐432         4/18         1.92                      0.42‐6.48    .36            ---    ---          ---         
  WHSC2‐103            7/15         0.51                      0.16‐1.43    .20            ---    ---          ---         
  HNRPL‐501            3/19         1.00                      0.22‐3.23    1.00           1.15   0.14‐10.59   .9          
  UBE2V‐43             11/11        0.79                      0.27‐2.16    .66            0.68   0.17‐2.79    .58         
  UBE2V‐85             1/21         ---                       ---          ---            ---    ---          ---         
  WHSC2‐141            12/10        0.82                      0.3‐2.32     .69            0.50   0.13‐1.96    .31         
  HNRPL‐140            5/17         3.97                      0.99‐14.19   .05            ---    ---          ---         
  SART3‐302            9/13         1.00                      0.31‐2.79    1.00           ---    ---          ---         
  SART3‐309            4/18         0.95                      0.21‐3.0     .93            0.60   0.1‐3.38     .56         
  A3 family (n = 16)   SART3‐109    3/13                      2.98         0.64‐10.85     .15    ---          ---         ---
  SART3‐511            8/8          1.09                      0.32‐3.45    .89            ---    ---          ---         
  *SART3‐734*          10/6         0.22                      0.06‐0.8     .02            0.22   0.05‐0.82    **.02**     
  Lck‐90               8/8          1.26                      0.39‐4.06    .70            ---    ---          ---         
  Lck‐449              4/12         0.69                      0.15‐2.34    .57            0.60   0.13‐2.24    .46         
  PAP‐248              5/11         3.84                      1.07‐13.25   .04            ---    ---          ---         
  Lck‐422              0/16         ---                       ---          ---            ---    ---          ---         
  CypB‐129             5/11         1.61                      0.42‐5.35    0.46           ---    ---          ---         
  WHSC2‐103            5/11         0.53                      0.12‐1.79    0.32           .44    0.09‐1.66    .23         

Peptides used for \<10% of patients were excluded from the univariate analysis.

Correlated peptides are shown in italics and significant *P‐*values are in shown in bold text.

CI, confidence interval; HR, hazard ratio; UC, urothelial cancer; ---, not applicable.

John Wiley & Sons, Ltd

###### 

Peptide‐specific IgG and CTL responses

  HLA type       Peptide     CRPC      Advance UC                                
  -------------- ----------- --------- ------------ -------- --------- --------- --------
  A24            SART2‐93    49        3 (6)        7 (14)   29        6 (21)    7 (24)
  SART3‐109      15          4 (27)    2 (13)       7        2 (29)    0         
  Lck‐208        0           ---       ---          9        0         0         
  PAP‐213        12          4 (33)    0            12       10 (83)   6 (50)    
  PSA‐248        29          19 (66)   3 (10)       11       5 (45)    0         
  EGF‐R‐800      19          1 (5)     0            7        2 (29)    3 (43)    
  MRP3‐503       1           1 (100)   0            0        ---       ---       
  MRP3‐1293      6           0         0            5        0         0         
  SART2‐161      10          3 (30)    1 (10)       3        0         1 (33)    
  Lck‐486        23          8 (35)    1 (4)        21       7 (33)    4 (19)    
  Lck‐488        40          6 (15)    6 (15)       26       5 (19)    4 (15)    
  PSMA‐624       2           0         0            5        1 (20)    2 (40)    
  EZH2‐735       2           0         0            1        1 (100)   1 (100)   
  PTHrP‐102      7           3 (43)    2 (29)       7        1 (14)    1 (14)    
  A2             CypB‐129    5         2 (40)       0        9         2 (22)    3 (33)
  Lck‐246        16          5 (31)    2 (13)       7        0         5 (71)    
  Lck‐422        0           ---       ---          1        0         0         
  ppMAPkkk‐432   8           0         0            2        0         0         
  WHSC2‐103      12          4 (33)    1 (8)        4        0         1 (25)    
  HNRPL‐501      8           5 (63)    0            3        2 (67)    2 (67)    
  UBE2V‐43       6           5 (83)    0            7        3 (43)    2 (29)    
  UBE2V‐85       0           ---       ---          0        ---       ---       
  WHSC2‐141      10          4 (40)    1 (10)       7        2 (29)    2 (29)    
  HNRPL‐140      5           2 (40)    1 (20)       1        0         0         
  SART3‐302      10          5 (50)    1 (10)       6        4 (67)    1 (17)    
  SART3‐309      9           3 (33)    0            3        1 (33)    0         
  A3             SART3‐109   4         2 (50)       1 (25)   3         1 (33)    0
  SART3‐511      9           1 (11)    0            8        1 (13)    1 (13)    
  SART3‐734      14          2 (14)    1 (7)        10       1 (10)    2 (20)    
  Lck‐90         13          4 (31)    2 (15)       6        2 (33)    2 (33)    
  Lck‐449        3           1 (33)    0            4        3 (75)    0         
  PAP‐248        3           1 (33)    0            5        1 (20)    0         
  Lck‐422        0           ---       ---          0        ---       ---       
  CypB‐129       3           0         0            4        0         0         
  WHSC2‐103      8           2 (25)    0            4        1 (25)    1 (25)    

CRPC, castration‐resistant prostate cancer; CTL, cytotoxic T lymphocyte; PPV, personalized peptide vaccine; UC, urothelial cancer; ---, not applicable.

John Wiley & Sons, Ltd

3.4. Effectiveness of peptides correlated with OS {#cas13709-sec-0012}
-------------------------------------------------

We also carried out an OS subgroup analysis based on groups stratified by use of correlated peptides according to HLA type (Figure [2](#cas13709-fig-0002){ref-type="fig"}). In CRPC, median OS times for patients with correlated peptides were significantly longer than for those without correlated peptides: 31.5 vs 16.9 months for HLA‐A24 (*P *=* *.01), 30.6 vs 8.7 months for HLA‐A2 (*P *\<* *.001) and 27.5 vs 18.1 months for HLA‐A3 family (*P *=* *.02). The median OS times for advanced UC patients with correlated peptides were also significantly longer than for those without correlated peptides: 8.3 vs 4.5 months for HLA‐A24 (*P *=* *.006), 13.4 vs 7.2 months for HLA‐A2 (*P *=* *.02) and 29.9 vs 9.7 months for HLA‐A3 family (*P *=* *.01).

![Kaplan‐Meier curves comparing overall survival with or without CP among CRPC (A) and advanced UC patients (B). CP, correlated peptide; CRPC, castration‐resistant prostate cancer; HLA, human leukocyte antigen; MST, median survival time; UC, urothelial cancer](CAS-109-2660-g002){#cas13709-fig-0002}

4. DISCUSSION {#cas13709-sec-0013}
=============

In the present study, we indicated using 265 advanced urological cancer patients treated by PPV that correlated peptides selected by both pre‐existing immunity and efficacy for OS significantly increased survival compared with peptides selected only by pre‐existing immunity. Importantly, analyzed survival data were obtained from a cohort of urological cancer patients who had equally poor prognostic backgrounds.

Most peptides previously used in cancer vaccines in clinical trials were able to induce peptide‐specific IgG or CTL responses but had no clinical benefits. This may be due to many factors, including the poor immunogenicity of TAA, inadequate peptide selection and tumor heterogeneity.[24](#cas13709-bib-0024){ref-type="ref"} In addition, the limited clinical efficacy may be a result of not knowing the immunological status of patients, which leads to mismatches between used peptides and heterogeneous immune cell repertoires.[3](#cas13709-bib-0003){ref-type="ref"} Upregulation of immune checkpoint molecules in tumor tissues after immunotherapy may also be a mechanism of peptide‐based vaccine failure. IFN‐γ secreted by activated T cells mediates programmed cell death 1 (PD‐1) expression by TIL and programmed cell death ligand 1 (PD‐L1) expression by tumor cells, respectively.[25](#cas13709-bib-0025){ref-type="ref"} Combination therapy with cancer vaccination and anti‐PD‐1 antibody in murine cancer models enhanced TIL antigen reactivity and prolonged the survival of tumor‐bearing mice.[26](#cas13709-bib-0026){ref-type="ref"}, [27](#cas13709-bib-0027){ref-type="ref"} We therefore expect combination therapy with peptide‐based vaccination and immune checkpoint blockade to be an effective strategy for peptide‐based vaccine failure or immune checkpoint blockade failure.

Unlike other peptide‐based vaccines, PPV is a novel immunotherapy approach for cancer patients. In PPV treatment, many suitable candidate peptides are selected based on HLA type and the pre‐existing host immunity. Conventional peptide‐based vaccines containing only 1 peptide may not initiate a specific antitumor response in tumor cell variants because of the loss or reduction in TAA.[28](#cas13709-bib-0028){ref-type="ref"} In this study, we found that the majority of TAA coding candidate peptides used in PPV treatment were expressed in tumor cells from prostate cancer or UC samples, except for p56Lck in both, and PSA, PAP and PSMA in the UC samples. However, p56Lck was expressed in TIL from all samples in this study. In a murine study, it was reported that inactivation of proximal T‐cell receptor (TCR) signaling blocked by the inhibitory motif of p56Lck inhibited TIL lytic function.[29](#cas13709-bib-0029){ref-type="ref"} Tumor‐induced lytic dysfunction of TIL may restrict T‐cell--based cancer immunotherapy. Therefore, p56lck is one of the important targets for cancer immunotherapy. Similar to previous reports, PSA and PAP were not expressed in UC samples.[30](#cas13709-bib-0030){ref-type="ref"}, [31](#cas13709-bib-0031){ref-type="ref"} However, ectopic expression of PSA has been reported in a variety of nonprostatic tumors, including UC of the bladder, breast cancer and melanoma.[32](#cas13709-bib-0032){ref-type="ref"}, [33](#cas13709-bib-0033){ref-type="ref"}, [34](#cas13709-bib-0034){ref-type="ref"} PSMA is a transmembrane receptor expressed on prostate cancer cells that is associated with a more aggressive phenotype. In the present study, PSMA was not expressed in some UC samples. However, a recent study indicated that PSMA is expressed in some subtypes of bladder cancer and is associated with tumor neovasculature based on IHC analysis.[35](#cas13709-bib-0035){ref-type="ref"} This report also suggested PSMA as a potential new vascular target for immunotherapy in UC patients.

Selection of clinically effective peptides is essential for peptide‐based cancer vaccines. In PPV treatment, up to 4 different peptides from 31 candidate peptides are given to individual patients based on HLA type and pre‐existing immunity by measuring peptide‐specific IgG levels, and the clinical benefits of PPV for advanced urological cancers have been reported.[4](#cas13709-bib-0004){ref-type="ref"}, [5](#cas13709-bib-0005){ref-type="ref"}, [6](#cas13709-bib-0006){ref-type="ref"} However, it is important to discriminate more clinically effective peptides among IgG‐positive peptide candidates prior to PPV treatment. To select peptides correlated with clinical efficacy, univariate and multivariate analyses with Cox regression hazards models were carried out. In the present study, patients with the following peptides had a significantly longer survival than patients without them (HR \<1.0, 95% CI \<1.0 and *P *\<* *.05): SART3‐109 (for HLA‐A24), PTHrP‐102 (for HLA‐A24), HNPRL‐140 (for HLA‐A2), SART3‐302 (HLA‐A2) and Lck‐90 (for the HLA‐A3 family) in CRPC patients, and EGF‐R‐800 (for HLA‐A24), Lck‐486 (for HLA‐A24), PSMA‐624 (for HLA‐A24), CypB‐129 (for HLA‐A2) and SART3‐734 (for the HLA‐A3 family) in advanced UC patients, respectively. These peptides induced peptide‐specific IgG and CTL responses and were considered to be peptides correlated with clinical benefits. In addition, the median OS times for both CRPC and advanced UC patients treated by PPV including correlated peptides were significantly longer than for those treated without correlated peptides. Selection of multiple epitopes for PPV treatment may reduce the risk of tumor escape through the existence and/or induction of antigen‐negative clones escaping peptide‐specific immune responses. It is relatively rare for tumor cells to escape peptide‐specific immune responses by simultaneously losing all antigens selected for vaccination.

Limitations of the present study include the exploratory nature of analyses, and that the study was based on a subset of patients from prospective trials of PPV treatment, making the present results not clinically applicable. Another limitation was that the correlated peptides were used with other peptides, although the survival of patients with contributing peptides was significantly longer than that of those without contributing peptides. The goal of the present study was to identify peptides with the greatest likelihood of enhancing PPV treatment. Although the present results are purely informative, this study may be used as a hypothesis‐generating rationale for further clinical trials of PPV treatment.

In conclusion, the use of correlated peptides selected by both survival data and pre‐existing immunity for PPV treatment may enhance the clinical benefits for urological cancer patients. To confirm these results, a clinical trial of novel PPV treatment for urological cancer patients is needed in which the peptides used for novel PPV treatment are first selected from correlated peptides and then up to 4 peptides are selected based on pre‐existing immunity according to HLA type.
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